First, the consumer packaged goods group. Campbell Soup and Clorox caught Cramer's attention, but the star by far was PepsiCo, with 3.5 percent organic growth and earnings per share up 11 percent on a constant currency basis.
The best drug company for Cramer was Johnson & Johnson, hands down. Earnings grew at 10.3 percent a share, worldwide sales rose 6.9 percent and domestic sales climbed 9.8 percent.
Read more from Mad Money with Jim Cramer
Cramer Remix: Biggest surprise for Valeant's new CEO
Cramer: Not enough $$ out there for S&P to rebound higher
Valeant's new CEO: I'm not in it for the money
Cramer still was singing the praise of McDonald's with its all-day breakfast concept, along with the spectacular quarters delivered by both Facebook and Amazon.
Next up were the industrials, and Cramer-fave Honeywell delivered again. CEO Dave Cote delivered a beat-and-raise quarter and confirmed the strength of China, which was the opposite of what everyone else said.
Next up was Accenture, the global consulting company, which surprised Cramer with how strong earnings were. As for the health care space, the only stand-out was United Health.
Cramer liked all the defense stocks. The world is restocking its arms stash, and the U.S. is an arms dealer. No matter what investors pick, he thinks it will be a winner.
"I know this sounds preposterous, but when you get winners in a typical earnings season, they tend to stay winners like a Super Bowl champion is the king until the next season. Same with these," Cramer said.
So, until conflicting reports are received, Cramer considers these to be his go-to champions of earnings season.